SV Life Sciences Fund IV

SVLSF IV closed in February 2007 with total commitments of $550 million (plus $22 million of co-investments committed by partners and individuals affiliated with SVLS).

As at 31 March 2010 the Fund had invested $316 million in 37 portfolio companies.

To go to individual portfolio companies websites please click on company logo.

Cardiomind: US

First Investment: 2007 - Early Stage

CardioMind is a medical device company developing novel nitinol-based stents and an innovative, balloon-free stent delivery system for small, difficult-to-access vessels.

---

Entellus: US

First investment: 2006 - Early Stage


Entellus is a company developing medical device therapies for nasal and sinus disease.

---

Halscion: US

First Investment: 2007 - Seed

Halscion is seed-stage company founded by The Innovation Factory which is developing a biomaterial for wound management.

---

LenSx Lasers, Inc: US

First Investment: 2008 - Start Up

LenSx is developing a novel computer controlled, femtosecond laser system that can integrate multiple refractive surgical procedures performed in the cornea and lens.

---

MindFrame: US

First investment: 2007 - Seed

MindFrame is a seed stage company formed out of Intersect Partners developing a novel mechanical device for the treatment of ischemic stroke.

---

Ocular Therapeutix: US

First Investment: 2008 - Start Up

I-Therapeutix is a medical device company that is currently engaged in development of in situ formed hydrogel therapeutic products specifically for ophthalmology.

Formerly known as I-therapeutics .

---

ReShape: US

First investment: 2005 - Seed

ReShape is a seed stage project within the Intersect Partners incubator developing an endoscopically placed device for the treatment of obesity.

---

Sadra Medical: US

First investment: 2003 - Seed

Sadra based in Campbell, CA, is developing an innovative new approach to aortic valve disease through a minimally invasive percutaneous replacement solution.

---

TransEnterix: US

First Investment: 2007 - Early Stage

TransEnterix is developing a surgical platform that provides all the benefits of a multi-port laparoscopic surgical approach while retaining a single port of entry through a natural body orifice or via the umbilicus.

---

ValenTx: US

First investment: 2009 - Early Stage

ValenTx, Inc., a medical device company, develops less invasive treatments for morbid obesity.

---